Abciximab biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 03 Jul 2015
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
- Mechanism of Action GPIIb-IIIa antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Coronary artery restenosis; Unstable angina pectoris